By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


EpiVax, Inc. 

146 Clifford Street

Providence  Rhode Island  02903  U.S.A.
Phone: 401-272-2123 Fax: 401-272-7562



Company News
EpiVax, Inc. Reports $5.2 Million For New Q Fever Vaccine Means There Is Hope For Vaccines On Demand 6/11/2015 11:14:48 AM
Novozymes Biopharma Enters License Agreement With EpiVax, Inc. To Advance Pioneering Treatment Of Autoimmune Diseases 12/23/2014 9:15:59 AM
EpiVax, Inc. Enters License Agreement With Novozymes Biopharma To Advance Pioneering Treatment Of Autoimmune Diseases 12/22/2014 9:21:31 AM
Chugai Pharmaceutical Co., Ltd. (Japan) Licenses ISPRI/Optimatrix Platform From EpiVax, Inc. For De-Risking Biologics 10/30/2014 9:27:40 AM
New Immunogenicity Analysis Tool Emerges From Dartmouth College-EpiVax, Inc.-University of Rhode Island Collaboration "In Silico" Host Cell Protein For Protein Therapeutics 7/8/2014 8:39:06 AM
BioAtla Combines EpiVax, Inc.'s Immunogenicity Screening Into Their Express Humanization™ Platform 4/24/2013 11:14:03 AM
EpiVax, Inc.-Novozymes Biopharma Tregitope-Albumin Fusion Moves "Paradigm-Shifting" Treatment for Diabetes Closer to Clinical Trials 2/12/2013 9:23:05 AM
Funding for Orphan Disease Indication Will Compare EpiVax, Inc.'s Tregitope with IVIG 11/19/2012 10:08:25 AM
EpiVax, Inc. Research on Tregitopes Wins 2010 AAPS Innovation in Biotechnology Award 5/25/2010 3:20:19 PM
EpiVax, Inc. Tregitope Technology: a Paradigm Shift 3/3/2010 1:02:25 PM